Next-Generation Regimens for Multiple Myeloma

EP. 1: Newly Diagnosed MM: Is RVd Still Standard of Care?

July 18th 2018

EP. 2: Optimizing Therapy for High-Risk Newly Diagnosed MM

July 18th 2018

EP. 3: Extrapolating from Clinical Trials: Daratumumab in MM

July 18th 2018

EP. 4: Optimizing Early Sequencing and Treatment in MM

July 18th 2018

EP. 5: Treatment Approaches in Relapsed Multiple Myeloma

July 18th 2018

EP. 6: Switching IMiDs: The OPTIMISMM Trial's Impact on MM

July 18th 2018

EP. 7: Selecting a Proteasome Inhibitor in Multiple Myeloma

July 18th 2018

EP. 8: Sequencing Through Multiple Lines of Therapy

July 18th 2018

EP. 9: Using MRD to Determine Cure in Multiple Myeloma

July 18th 2018

EP. 10: Evaluating MRD's Role in Multiple Myeloma

July 18th 2018

EP. 11: The Promise of Anti-BCMA CAR T-Cell Therapy in MM

July 18th 2018

EP. 12: Optimizing the Use of Anti-BCMA Therapy in MM

July 18th 2018

EP. 13: Considering Selinexor in Penta-Refractory Myeloma

July 18th 2018

EP. 14: Venetoclax: Potential Use in Multiple Myeloma

July 18th 2018

EP. 15: Addressing Treatment of Myeloma-Related Comorbidity

July 18th 2018

EP. 16: Multiple Myeloma: Closing Considerations for Treatment

July 18th 2018